Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Alphabet To Appeal €4.1B EU Antitrust Fine

Legal
News

Alphabet To Appeal €4.1B EU Antitrust Fine

-Reuters

byBill Haddad

October 27, 2022

1 minute read

-Reuters

Magna International Updated FY23 Revenue Expectation To $42.1B-$43.1B (Prior $41.9B-$43.5B) Vs Consensus Of $42.47B

By Benzinga Newsdesk

November 3, 5:15 AM

2023 OUTLOOK We first disclose a full-year Outlook annually in February, with quarterly updates. The following Outlook is an update to our previous Outlook in August 2023. Updated 2023 Outlook

MGA

This Healthcare Stock is Down By More Than 50%: Here’s 25 Stocks Moving Premarket

By Lisa Levin

July 13, 6:22 AM

Gainers

ABVC

Moderna CEO Takes Charge of Sales Amid Push for COVID Vaccine and RSV Launch in 2024

By Benzinga Newsdesk

December 12, 9:06 AM

Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and

MRNA

News

Better Therapeutics Completes Enrollment In Real-World Evidence Program Evaluating Long-Term Effectiveness Of AspyreRx In Type 2 Diabetes

By Benzinga Newsdesk

September 28, 4:18 PM

1,000 participants enrolled across two studies, and six sitesStudies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilizationBetter Therapeutics, Inc. (NASDAQ:BTTX), a

BTTX

Alphabet To Appeal €4.1B EU Antitrust Fine

Related Posts

Magna International Updated FY23 Revenue Expectation To $42.1B-$43.1B (Prior $41.9B-$43.5B) Vs Consensus Of $42.47B

This Healthcare Stock is Down By More Than 50%: Here’s 25 Stocks Moving Premarket

Moderna CEO Takes Charge of Sales Amid Push for COVID Vaccine and RSV Launch in 2024

Better Therapeutics Completes Enrollment In Real-World Evidence Program Evaluating Long-Term Effectiveness Of AspyreRx In Type 2 Diabetes